During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure. After the failure of frontline erythropoiesis-stimulating ...
FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results